Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.62 |
| ▸ | JAK1 | P23458 | 4/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504386 | 0.78 | NUDT1 (0.62) | NUDT1JAK1EGLN2JAK3KDM4E | |
| SCHEMBL12518501 | 0.74 | NUDT1 (0.58) | NUDT1JAK1EGLN2JAK3 | |
| Cyclopropane SCHEMBL16986946 | 0.74 | JAK1 (0.50) | JAK1EGLN2JAK3 | |
| SCHEMBL13449511 | 0.73 | NUDT1 (0.51) | NUDT1JAK1EGLN2JAK3KDM4E | |
| SCHEMBL2144054 | 0.73 | NUDT1 (1.00) | NUDT1JAK1EGLN2JAK3KDM4E | |
| SCHEMBL13031181 | 0.72 | JAK1 (0.70) | JAK1JAK3 | |
| SCHEMBL3095594 | 0.70 | PIK3CG (0.43) | NUDT1 | |
| SCHEMBL22499606 | 0.70 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3KDM4E | |
| SCHEMBL28678298 | 0.70 | NUDT1 (0.56) | NUDT1JAK1EGLN2JAK3 | |
| SCHEMBL3601961 | 0.69 | NUDT1 (0.78) | NUDT1JAK1EGLN2JAK3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | claimed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | claimed |
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | claimed |
| US-9012633-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-21 | — | — | US | claimed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | claimed |
| EP-2217578-B9 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-09-10 | — | — | EP | claimed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | claimed |
| EP-2217578-B1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2013-12-04 | — | — | EP | claimed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | claimed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | claimed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2217578-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-08-18 | — | — | EP | claimed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | claimed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | claimed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | claimed |
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| EP-1894931-A1 | Triazole derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | ITK, PIK3C3, TXK | NUDT1 2884/4885JAK1 13/4885EGLN2 1996/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | NUDT1 2497/4885JAK1 14/4885EGLN2 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.